Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Open Monoclonal Technology Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11475
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Open Monoclonal Technology Inc (OMT), a subsidiary of Ligand Pharmaceuticals Inc, is a biotechnology company that discovers and develops human monoclonal antibody platform based on transgenic rats. The company provides products such as omnirat, omnimouse and omniflic. Its omnirat is an antibody platform that generates human monoclonal antibodies based on transgenic rats. OMT’s omnimouse is a transgenic mouse that complements omnirat and expands epitope coverage. The company’s omniflic is the rat engineered with a fixed light chain for discovery of bi-specific, fully human antibodies. It serves pharmaceutical and biotech companies. The company offers alternative to generating and characterizing human antibody development candidates. OMT is headquartered in San Diego, California, the US.

Open Monoclonal Technology Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Symphogen Enters Into Agreement With Open Monoclonal Technology 11
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 12
Open Monoclonal Expands Agreement with CNA Development 13
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 14
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 15
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 16
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 17
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 18
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 19
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 21
Open Monoclonal Enters into Licensing Agreement with Celgene 22
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 23
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 24
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 25
Open Monoclonal Enters into Licensing Agreement with Amgen 26
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 27
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 28
Acquisition 29
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 29
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 30
Open Monoclonal Technology Inc – Key Competitors 31
Open Monoclonal Technology Inc – Key Employees 32
Open Monoclonal Technology Inc – Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Key Facts 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Symphogen Enters Into Agreement With Open Monoclonal Technology 11
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 12
Open Monoclonal Expands Agreement with CNA Development 13
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 14
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 15
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 16
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 17
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 18
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 19
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 21
Open Monoclonal Enters into Licensing Agreement with Celgene 22
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 23
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 24
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 25
Open Monoclonal Enters into Licensing Agreement with Amgen 26
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 27
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 28
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 29
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 30
Open Monoclonal Technology Inc, Key Competitors 31
Open Monoclonal Technology Inc, Key Employees 32

List of Figures
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ingredia Nutritional:企業の戦略・SWOT・財務情報
    Ingredia Nutritional - Strategy, SWOT and Corporate Finance Report Summary Ingredia Nutritional - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Five Prime Therapeutics Inc (FPRX):医療機器:M&Aディール及び事業提携情報
    Summary Five Prime Therapeutics Inc (Five Prime) is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company’s developmental pipeline is based on the discovery platform and library of therapeutic protei …
  • Nikon Corporation:企業の戦略・SWOT・財務情報
    Nikon Corporation - Strategy, SWOT and Corporate Finance Report Summary Nikon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Dynavax Technologies Corp (DVAX):企業の財務・戦略的SWOT分析
    Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Tongaat Hulett Ltd (TON):企業の財務・戦略的SWOT分析
    Tongaat Hulett Ltd (TON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Alamo Group Inc (ALG):企業の財務・戦略的SWOT分析
    Alamo Group Inc (ALG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cogstate Ltd (CGS):企業の財務・戦略的SWOT分析
    Summary Cogstate Ltd (Cogstate) is a cognitive science company that provides technology solutions. The company offers scientific consulting, precision recruitment and computerized assessment, among others. It also provides drug development strategies, protocol design, test selection for screening, s …
  • MMC Corp Bhd (MMCCORP):企業の財務・戦略的SWOT分析
    Summary MMC Corp Bhd (MMC) is an investment holding company which carries out mining, mineral exploration and construction services. It operates through ports and logistics, energy and utilities, engineering and industrial development divisions. The company offers containers, bulk and breakbulk, liq …
  • Hino Motors, Ltd.:企業の戦略・SWOT・財務分析
    Hino Motors, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hino Motors, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Midsona AB (MSON B):企業の財務・戦略的SWOT分析
    Summary Midsona AB (Midsona), formerly Midelfart Sonesson AB is a healthcare products manufacturing company that provides personal care products, health foods, and hygiene products. The company’s products include superfood, sports nutrition, dietary supplements, nutritional supplements, organic food …
  • BELECTRIC GmbH:電力:M&Aディール及び事業提携情報
    Summary Belectric GmbH (Belectric) is a renewable energy company that offers solar systems and solutions. The company manufactures, designs, and constructs photovoltaic rooftop installation systems for solar-projects and ground-mounted solar power plants. It manufactures BoS components, photovoltaic …
  • U.S. Army Institute of Surgical Research:製薬・医療:M&Aディール及び事業提携情報
    Summary U.S. Army Institute of Surgical Research (USAISR), a subsidiary of U.S. Army, is a medical research center that offers solutions for burn, trauma, and combat casualty care from time of injury to rehabilitation. The center conducts research in the areas of dental and trauma research detachmen …
  • Cofidis Participations S.A.
    Cofidis Participations S.A. - Strategy, SWOT and Corporate Finance Report Summary Cofidis Participations S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …
  • Samyang Comtech Co., Ltd.:企業の戦略・SWOT・財務情報
    Samyang Comtech Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samyang Comtech Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Alert Logic Inc:企業の戦略的SWOT分析
    Alert Logic Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Andeavor (ANDV):企業の財務・戦略的SWOT分析
    Andeavor (ANDV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Eastman Chemical Co (EMN):企業の財務・戦略的SWOT分析
    Eastman Chemical Co (EMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • China Vanke Co., Ltd.:企業の戦略・SWOT・財務情報
    China Vanke Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary China Vanke Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆